发布求助
搜索
全部 求助中 待确认 已完结
其它数据库
求助中 The antibody–drug conjugate SHR-A1904 for targeting CLDN18.2 in advanced gastric or gastroesophageal junction cancer: a phase 1 trial
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer The DEPEND Phase 2 Nonrandomized Clinical Trial
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Adjuvant Nivolumab vs Observation in Resected Non-Small Cell Lung Cancer: A Randomized Clinical Trial.
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Regulation of immune checkpoint molecules in cancer immune evasion and therapy
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Addition of ipilimumab to atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (PRODIGE 81-FFCD 2101-TRIPLET HCC): phase 2 results from a randomised, multicentre, open-label, phase 2–3 trial
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Multimodality curative-intent treatment in NSCLC: an unprecedented era of change 2017–2025
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
Elsevier
求助中 Glecirasib plus sitneprotafib in patients with KRASG12C-mutated non-small-cell lung cancer in China: an open-label, multicentre, single-arm, phase 1/2a trial
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 First-Line Sunvozertinib in NSCLC with EGFR Exon 20 Insertion Mutations
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Outcomes and Treatments of Patients With Non–Small Cell Lung Cancer Who Received Pembrolizumab
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Micro evidence affecting the improvement of carbon accounting information disclosure in China——taking listed companies in high energy consuming industries as an example
准备好了 准备好了
2026-09-02
10
我要应助
其它数据库
求助中 Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
Elsevier
求助中 Conversion therapy of tislelizumab plus lenvatinib and GEMOX in unresectable locally advanced biliary tract cancer (ZSAB-TransGOLP): a multicentre, prospective, phase 2 study
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Chinese expert consensus on radiotherapy combined with immunotherapy for unresectable lung cancer (2026 Edition)
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis.
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
Elsevier
求助中 Intratumoral heterogeneity and immunotherapy resistance: clinical implications
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 The next generation of antibody–drug conjugates
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助
其它数据库
求助中 First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial
用户Hk9Gh1 用户Hk9Gh1
2026-09-02
10
我要应助